Reactivity of biologically important reduced pyridines. IV. Effect of substitution on ferricyanide-mediated oxidation rates of various 1,4-dihydropyridines
[EN] IMIDOTHIAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS IMIDAZOTHIAZOLIQUES DE KINASES
申请人:MERCK SHARP & DOHME
公开号:WO2011037780A1
公开(公告)日:2011-03-31
The present invention is directed to novel kinase inhibitors of general formula (I) and pharmaceutically acceptable salts thereof, and to the use of the kinase inhibitors of general formula (I) for treating diseases or disorders in which tau phosphorylation and cell cycle regulation is implicated, such as Alzheimer's Disease and cancer.
Sadykow; Maksimow, Zhurnal Obshchei Khimii, 1946, vol. 16, p. 1719,1725
作者:Sadykow、Maksimow
DOI:——
日期:——
IMIDOTHIAZOLE KINASE INHIBITORS
申请人:Merck Sharp & Dohme Corp.
公开号:EP2480076A1
公开(公告)日:2012-08-01
Reactivity of biologically important reduced pyridines. IV. Effect of substitution on ferricyanide-mediated oxidation rates of various 1,4-dihydropyridines
作者:Marcus E. Brewster、Agnes Simay、Klara Czako、David Winwood、Hassan Farag、Nicholas Bodor
DOI:10.1021/jo00276a039
日期:1989.7
A Study of the Primary Acid Reaction on Model Compounds of Reduced Diphosphopyridine Nucleotide<sup>1,2</sup>